Abstract: Hematological malignant tumor patients are prone to coagulation disorders, represented by acute leukemia(AL), and the incidence of lymphoma coagulation disorders is also high and venous thromboembolism (VTE) caused by coagulopathy is one of the main causes of death. The incidence of lymphoma thromboembolism in non-Hodgkin lymphoma(NHL) is significantly higher than that in Hodgkin lymphoma(HL). The occurrence of VTE can form coagulation waterfall and promote tumor growth, indicating the disease progression and deterioration of patients. Risk factors and related characteristics of lymphoma VTE can be used as the basis for early clinical drug intervention to improve the prognosis of patients and greatly improve the quality of life.